is that we lower the threshold for AD pathology to Braak stage III NFTs plus sparse neuritic plaques in LB+ individuals, suggesting that LB pathology commonly occurs in APOE-ε4 carriers with potential early-stage AD but not in firmly non-AD APOE-ε4 carriers. This evidence concerns the gene APOE and Alzheimer disease.